
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is a leader in a structurally growing market, supported by global trends such as aging populations and increasing prevalence of obesity. Their recent focus on digital health and strong financials, including a projected revenue growth of 5-7% in FY27, make them an attractive investment opportunity with a positive outlook for future growth and potential for shareholder returns. The company's commitment to sustainability and diversity adds to their overall appeal and aligns with the current societal and market expectations.
Bears say
ResMed is facing several challenges that may negatively impact its financial performance and stock value in the near future, including a gross margin miss and potential contraction in gross margins in the upcoming quarter due to cost inflation and higher freight costs. Additionally, the company's growth in the Americas market has been weaker than expected, and its tax rate has increased. There is also a potential risk for a large acquisition that may not be as value-accretive as expected. While ResMed has made efforts to innovate and expand into digital health, the potential for new products or therapies to disrupt its offerings remains a concern. As a result, a negative outlook can be justified for ResMed's stock, as these fundamental factors may hinder its financial performance and stock price in the future.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares